Spyre Therapeutics (SYRE) News Today $15.16 -0.08 (-0.52%) Closing price 04:00 PM EasternExtended Trading$15.00 -0.16 (-1.06%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYRE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Spyre Therapeutics (NASDAQ:SYRE) Receives "Outperform" Rating from WedbushAugust 7 at 12:36 PM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPSAugust 6 at 4:18 PM | marketbeat.comSpyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 5 at 4:02 PM | globenewswire.comTD Asset Management Inc Has $361,000 Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)August 5 at 3:44 AM | marketbeat.comJefferies Financial Group Inc. Acquires 31,900 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)August 2, 2025 | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsAugust 1, 2025 | globenewswire.comSpyre Therapeutics (SYRE) Projected to Post Quarterly Earnings on WednesdayJuly 31, 2025 | marketbeat.comVictory Capital Management Inc. Sells 16,230 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)July 28, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of "Buy" by AnalystsJuly 17, 2025 | marketbeat.comHere's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn SituationJuly 16, 2025 | finance.yahoo.comSpyre Therapeutics (NASDAQ:SYRE) Shares Down 7.8% - Time to Sell?July 15, 2025 | marketbeat.comSYRE - Spyre Therapeutics Inc Trailing Returns - MorningstarJuly 4, 2025 | morningstar.comMSpyre Therapeutics Announces Grants of Inducement AwardsJuly 3, 2025 | globenewswire.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Recommendation of "Buy" from AnalystsJune 22, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and UnitedHealth (UNH)June 20, 2025 | theglobeandmail.comSpyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways ForwardJune 18, 2025 | seekingalpha.comSpyre Therapeutics (NASDAQ:SYRE) Shares Down 7.7% - Here's WhyJune 17, 2025 | marketbeat.comSpyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development ...June 17, 2025 | finanznachrichten.deSpyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 ReadoutsJune 17, 2025 | prnewswire.comSpyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025June 16, 2025 | prnewswire.comBank of America Corp DE Reduces Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)June 16, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Up 7.5% - Time to Buy?June 10, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 22,540 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)June 10, 2025 | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsJune 6, 2025 | prnewswire.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Up 7.1% - Here's What HappenedJune 4, 2025 | marketbeat.com122,153 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Universal Beteiligungs und Servicegesellschaft mbHJune 3, 2025 | marketbeat.comWellington Management Group LLP Has $37.35 Million Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)June 1, 2025 | marketbeat.comMillennium Management LLC Acquires Shares of 167,804 Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 31, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Sold by Voloridge Investment Management LLCMay 29, 2025 | marketbeat.comSpyre Therapeutics to Participate in Upcoming June Investor ConferencesMay 28, 2025 | prnewswire.comBNP Paribas Financial Markets Takes $437,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 27, 2025 | marketbeat.comWoodline Partners LP Grows Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 25, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Northern Trust CorpMay 21, 2025 | marketbeat.comRTW Investments LP Raises Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 18, 2025 | marketbeat.comPolar Capital Holdings Plc Grows Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 18, 2025 | marketbeat.comProsight Management LP Buys New Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 17, 2025 | marketbeat.comJanus Henderson Group PLC Buys 336,209 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 17, 2025 | marketbeat.comParadigm Biocapital Advisors LP Grows Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 16, 2025 | marketbeat.comJefferies Financial Group Inc. Has $28.33 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 13, 2025 | marketbeat.comFirst Trust Advisors LP Invests $548,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 12, 2025 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Spyre Therapeutics (SYRE), Fresenius Medical Care (FMS) and Jazz Pharmaceuticals (JAZZ)May 10, 2025 | theglobeandmail.comDeerfield Management Company L.P. Series C Purchases Shares of 450,000 Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 10, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Holdings Raised by Driehaus Capital Management LLCMay 10, 2025 | marketbeat.comSpyre Therapeutics, Inc.: Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 9, 2025 | finanznachrichten.deDeep Track Capital LP Lowers Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 9, 2025 | marketbeat.comSpyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | prnewswire.comBraidwell LP Grows Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 8, 2025 | marketbeat.comBlackstone Inc. Acquires 156,206 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 8, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Down 5.8% - Here's WhyMay 7, 2025 | marketbeat.comInvesco Ltd. Sells 118,195 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 6, 2025 | marketbeat.com Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address SYRE Media Mentions By Week SYRE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYRE News Sentiment▼1.120.38▲Average Medical News Sentiment SYRE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYRE Articles This Week▼84▲SYRE Articles Average Week Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KRYS News Today MTSR News Today ABVX News Today ZLAB News Today AKRO News Today ACLX News Today ACAD News Today VKTX News Today SRRK News Today PTCT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SYRE) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
